Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Aflibercept (Eylea) for therapy of choroidal neovascularizations in pseudoxanthoma elasticum
2014-005263-33Phase 2
Key facts
- Status
- Completed
- Start
- Feb 2015
- Countries
- 1
- Sponsor
- University of Bonn Faculty of Medicine
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Drugs
- aflibercept
- Conditions
- Subretinal neovascularizationpseudoxanthoma elasticum (PXE)
01
Overview
Phase 2, single-arm trial of aflibercept in Subretinal neovascularization and pseudoxanthoma elasticum (PXE), sponsored by University of Bonn Faculty of Medicine. Started Feb 2015; status: completed.
02
Design
1 arm- Study design
- Non-randomizedSingle group
Intravitreal aflibercept
Single-arm treatment with intravitreal aflibercept (Eylea) for choroidal neovascularizations and fibrovascular proliferations in patients with pseudoxanthoma elasticum.
03
Who it enrols
Adult patients diagnosed with pseudoxanthoma elasticum who have choroidal neovascularizations or fibrovascular proliferations; no healthy volunteers.
Beyond the preview
Go deeper on 2014-005263-33.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005263-33.